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The term “vulvovaginitis” encompasses a broad 
and heterogeneous number of conditions, which, 
contrarily to what the suffix “-itis” implies, are 
not necessarily infectious (e.g. cytolytic vagino-
sis [CyV]) or inflammatory (e.g. bacterial vagi-
nosis [BV]).
The clinical or symptomatic approach to the 
management of vulvovaginitis is very limited; 
a significant number of women will not fit the 
“traditional” diagnosis of candidiasis, BV, or 
trichomoniasis. A proper approach, encompass-
ing other neglected diagnoses, will reduce the 
number of women without a diagnosis (reported 
to be as high as 30%), and lead to more adequate 
treatments.
These entities, despite not life-threatening, 
can seriously contribute to impair the quality of 
life of affected women at all levels, and leave 
deep and long lasting psychosexual sequelae.
24.2  Vulvovaginal Candidiasis (or 
Candidosis)
It is debatable whether the symptomatic presence 
of fungi from the genera Candida in the vagina 
should be referred to as vulvovaginal “candidia-
sis” or “candidosis” (VVC), since inflammation 
is not always present, and “-osis” is the suffix 
usually used for fungal infections.
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Candidiasis: Breaking the Myths
• A significant number of women will not 
fit the “traditional” diagnosis of candi-
diasis, BV, or trichomoniasis
• Candida albicans infection does not 
consist only of vaginal discharge. In 
fact, its mycelium can penetrate the vag-
inal mucosa, up to 10 layers of cells 
deep.
• Despite the long list of risk factors and 
associations with vulvovaginal candidi-
asis (VVC), most of the times a precipi-
tating factor cannot be identified.
• Itch is the most notorious symptom of 
VVC—but most women with itching do 
not have a VVC.
• Identification of Candida in cultures, 
per se, cannot be assumed as a diagnosis 




24.2.1  Aetiology 
and Pathophysiology
Approximately 90% of the cases of VVC are 
caused by C. albicans. The next most common 
agent is C. glabrata; much less frequently (<1–
2% of the total), C. krusei, C. tropicalis, C. dub-
liniensis and C. parapsilosis, among others, can 
also be involved [1]. The non-albicans Candida 
(NAC) species are more commonly encountered 
in cases of recurrent VVC (in up to 20%), and in 
diabetic or immunocompromised women.
Co-infection is uncommon (<10% of cases) 
and usually the involved species are C. albicans 
and C. glabrata [1].
Candida is commonly found in the form of 
blastospores in the mucous layer, as a commen-
sal. Infection starts with adherence to vaginal 
epithelial cells, mediated by mannoproteins. For 
the species that form mycelium (C. albicans), 
it is a fundamental step in eliciting an immune 
response and in causing host cell damage. The 
mycelium, in a phenomenon mediated, among 
others, by candidalysin, penetrates the vaginal 
mucosa, up to 10 layers of cells deep [2].
The first line of defence, innate immunity, 
includes phagocytosis by neutrophils and mac-
rophages, activation of the complement cascade, 
direct cellular killing, and promotion of opsoniza-
tion via complement receptors. This process is 
mediated by the binding of mannose-binding lec-
tin (MBL) to Candida and explains why women 
with mutations of the MBL gene, especially at the 
codon 54, are more prone to recurrent VVC [3].
Acquired immunity against Candida is mostly 
mediated by IgA secretion, as well as a Th2 type 
cytokine profile response. However, an impaired 
Th1 response has been associated with increased 
risk of recurrent VVC [4].
A normal lactobacillary flora is protec-
tive against VVC due to: (1) competition for 
nutrients, (2) competition for adhesion sites, 
(3) production of biosurfactants that decrease 
the adherence of Candida, (4) production of 
H2O2, (5) production of toxic peptides and fatty 
acids, (6) downregulation of genes responsible 
for the biofilm production, and (7) inhibition of 
filamentation [5]. Interestingly however, most 
cases of VVC occur in women with normal 
flora [2] (Fig. 24.1).
24.2.2  Prevalence and Epidemiology
VVC is not a reportable disease, thus all preva-
lence data are based on studies performed in dif-
ferent settings, often not representative of the 
population, and looking for different outcomes [1].
It is considered the second most frequent cause 
of “vulvovaginitis” symptoms, after BV. Candida 
can be responsible for the symptoms of vulvo-
vaginitis in up to 30% of cases [6]. However, the 
perception of its prevalence, from patients’ and 
health care providers’ point of view, is higher; 
most cases are treated with over-the- counter med-
ication, without proper confirmation.
Vaginal Candida colonization is found in 
at least 10–20% of healthy, reproductive age, 
asymptomatic women [7]. It is higher in preg-
nant women (20–40%), especially in the third 
trimester, due to the high levels of estrogens, and 
in immunocompromised women [8]. The cumu-
lative incidence of colonization over 1 year is as 
high as 70% [9].
Up to 75% of women will experience at least 
one episode during their life time [1]. Half of 
these will suffer at least one additional episode 
and 5–10% will have recurrent VVC (Table 24.1) 
[1, 6, 10].
There is no data suggesting an increase in the 
incidence of VVC over the years [2].
Fig. 24.1 Typical curdy white discharge of VVC (cul-
tures were positive for C. krusei)




The majority of episodes of VVC (90%) are 
considered uncomplicated. When the episodes 
are recurrent, associated with severe symptoms, 
caused by NAC species, or occur in diabetic or 
immunocompromised patients, it is classified as 
complicated [10] (Table 24.1).
According to most societies’ guidelines, 
recurrent VVC is defined as four or more symp-
tomatic episodes in 1 year. Most do not refer the 
need for a laboratorial confirmation (wet mount, 
culture, Gram staining) of every episode. We 
support that confirmation is necessary, in order 
to exclude alternative diagnosis (cytolytic vagi-
nosis, allergic vaginitis) or NAC species.
24.2.4  Risk Factors and Associations
Despite the long list of risk factors and associa-
tions with VVC (Table 24.2), most of the times a 
precipitating factor cannot be identified [11].
The presence of Candida is highly related 
to oestrogen levels, and, accordingly it is much 
less common in prepubertal and postmenopausal 
women, and, contrarily, more common in preg-
nant women.
The role of oestrogens is complex: (1) pro-
motes Candida proliferation and virulence, (2) 
induces immunological tolerance, and (3) pro-
motes the production of glycogen by the vaginal 
epithelium cells. Progesterone, on one side, pro-
motes Candida proliferation, but on the other has 
been shown also to inhibit its ability of forming 
biofilms and mycelium [12, 13].
The role of oral contraceptives in VVC is 
controversial. Modern low dose pills seem to 
pose a low risk, if any. Progestin-only pills and 
subdermal progestin implants seem to be associ-
ated with a lower risk of colonization, probably 
due to the relative state of hypoestrogenism they 
induce [14].
Copper intrauterine devices (IUDs) and, more 
recently, also levonorgestrel-releasing intrauter-
ine systems (LVG-IUS) were associated with an 
increased risk of colonization by Candida [14, 
15]. The formation of biofilms in the IUDs/LVG- 
IUS, to which Candida can adhere and act as a 
reservoir, is a possible explanation. However, 
this phenomenon does not seem to occur with the 
vaginal ring [16].
Glycogen, which is increased in cases of high 
levels of oestrogens, of steroids use, and in dia-
betic women, is the main growth substrate for 
Candida [12].
In women colonized with Candida, the use of 
antibiotics and the consequent destruction of the 
vaginal lactobacilli is a well-established risk fac-
tor [6] (Table 24.2).
Factors that can decrease the inflammatory 
response are associated with VVC. These can be 
genetic (MBL gene polymorphisms, diabetes) or 
acquired (HIV, drugs, low zinc levels).
Behavioural and environmental factors are 
the most complex ones to understand and with 
the most disparate results across studies. Higher 
temperatures and increased moisture, whether 
derived from the climate or local conditions 
(obesity, non-breathable clothes, etc.) seem to be 
related to increased rates of VVC. Some authors 
consider panty liners a risk factor for VVC, but 
systematic reviews do not support it [17].
Table 24.1 Classification of VVC
Uncomplicated All 4 criteria must be met:
 • Sporadic or infrequent
 • Mild-to-moderate symptoms
 • Caused by Candida albicans
 •  Non immunocompromised  
woman
Complicated Any of these criteria present:
 • Recurrent VVC
 •  Severe (extensive vulvar  
erythema, oedema, excoriations 
and fissures)
 • Non-albicans species involved
 •  Women with diabetes, pregnancy, 
immunocompromising  
conditions (e.g. HIV infection), 
debilitation, or 
immunosuppressive therapy (e.g. 
corticosteroids)
Recurrent  •  Four or more symptomatic 
episodes within 1 year
 •  Each episode must have 
laboratorial confirmation  
(not recommended by all  
societies)
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Table 24.2 Risk factors associated with VVC
Hormonal factors Consequences/mechanisms of action
 • Increased oestrogen levels (e.g. pregnancy)
 • Menopausal hormonal replacement therapy
 • Oral contraceptives (?)
 •  ↑ Adherence of Candida to vaginal cells
 • ↑ Mycelium formation
 • ↓ Vaginal immunological response
 • ↑ Levels of vaginal glycogen
 •  Direct stimulation of Candida proliferation
Metabolic factors
 • Obesity
 • Diabetes mellitus
 •  ↑ Adherence of Candida do vaginal cells
 • ↑ Levels of vaginal glycogen
 • ↓ Vaginal immunological response
 • Low zinc levels  • ↓ Cellular immunity
Host factors
 • Immunosuppression (e.g. HIV)
 • Debilitating illnesses
 • Stress
 • ↓ Immunological defences
 •  Genetic polymorphisms (MBL gene, IL4 gene, 
NALP3, dectin-1 gene, CARD9, STAT1, STAT3)
 • ↓ Immunological defences
 • ABO-Lewis nonsecretor blood type  • ↓ Inhibition of adherence lectins
 • ↓ IgA levels
 •  Carbohydrates metabolism abnormalities
 • Atopy/allergy history  •  Excessive reaction to Candida antigens
 • Black race  • Genetic factors?
Drugs
 •  Antibiotics (topical and systemic) (mostly beta-
lactamics, macrolides, and tetracyclines)




 • ↓ Immunological defences
Behavioural factors
 • Hot and humid climates
 • Tight and synthetic clothes
 • Patny-liners (?)
 • Obesity
 • ↑ Moisture and temperature
 • Bad hygienic habits
 • Vaginal douching
 • Swimming pools rich in chloride
 •  ↑ Spore load (from the intestinal reservoir)
 • ↑ Vaginal pH
 • Destruction of lactobacilli
 • Dietary factors (rapid sugars)  • ↑ Glycogen
 •  Sexual habits (frequent sexual intercourse, recipient 
oral sex) (Controversial: early sexual debut, new or 
multiple partners, intercourse during menses)
 • ↑ Spore load
 • Alteration of the flora by semen
 •  Exposure to cytokines, antigens, prostaglandins, and 
antibodies from semen
 •  Transmission from the oral mucosa (?)
  • Copper IUDs/ LNG-IUS  •  Formation of biofilms, that increase adherence and act 
as reservoirs
 • Changes in the vaginal flora
VVC is not considered STI, but it is sexually 
related. Sexual intercourse and the  deposition of 
semen in the vagina changes the pH, the interleu-
kin and prostaglandin milieu, exposes the vagina 
to IgE and antibodies from the male partner, 
which can be responsible for the development of 
symptoms of VVC.
24.2.5  Signs and Symptoms
The reservoir of Candida, during an active epi-
sode of VVC is the vagina, which is devoid of 
itch receptors, thus the symptoms manifest only in 
the vulva. It is not known, if itch is caused by the 
infection itself or secondary to the contact with the 
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vaginal discharge. In severe cases, manifestations 
of VVC such as redness and oedema may extend 
up to the perianal area and the intercrural folds 
(Fig. 24.2). Satellite vulvar lesions can be present.
Itch is the most notorious symptom of VVC—
but it must be kept in mind that most women 
with itching do not have a VVC [18]. Especially 
in cases of hypoestrogenism, in the absence of 
immunodepression, VVC is not likely to be the 
cause of itching.
Other symptoms can include entry dyspareu-
nia, soreness, and irritation. The presence of NAC 
is usually asymptomatic; if not, it usually causes 
burning, rather than itching, and the symptoms 
tend to be milder.
Women can describe a more abundant, curdy, 
white and thick (cheese-like) or watery discharge, 
without an offensive smell (Fig. 24.1). It can also 
be absent, especially in chronic VVC.
Fissures and excoriations can cause vulvar 
pain and terminal or post-micturition dysuria—
derived from the contact of urine with the lesions, 
rather than from urethral involvement. Oedema 
can be present, more exuberantly in the labia 
minora, and vulvar redness is seen in up to 40% 
of cases [2]. The vagina and cervix may be cov-
ered with a white, cheesy discharge (Fig. 24.2), 
but usually do not look inflamed and there is no 
cervicitis, but minor bleeding can be noticed if 
removal of the discharge plaque from the vaginal 
wall is attempted [2].
The severity of symptoms can fluctuate 
along the menstrual cycle, worsening in the 
week prior to menses and improving during it. 
It can be explained by the vaginal epithelial cell 
proliferation and cytolysis, mediated by oestro-
gens and progesterone, respectively, which ulti-
mately leads to increased levels of glycogen in 
the vagina. The raising of the pH mediated by 
the presence of blood and endometrial debris 
in the vagina leads to a decrease in the 
symptoms.
24.2.6  Complications
VVC, especially the complicated form, is a 
major cause of mental suffering, depression, low 
self-esteem, with impact on sexual and affective 
relations.
A large majority of newborns who are colo-
nized with C. albicans during a vaginal delivery 
will develop oral candidiasis or napkin dermatitis 
during their first year of life. This can be dimin-
ished by treating colonized mothers during the 
3rd trimester [2].
Petricevic et al. have found slight increases in 
preterm labour and risk of low birth weight rates, 
especially if colonization is present during the 
2nd trimester of pregnancy [19].
Candida chorioamnionitis has been reported, 
but it is a very rare event and usually related to 
procedures such as in vitro fertilization, cérclage, 
or amniocentesis [20].
In one study, the presence of Candida was 
significantly associated with an increased risk of 
seroconversion in HIV negative women, with a 
seropositive male partner [21].
VVC has been associated with vulvodynia 
in several studies but most of the reported epi-
sodes are based on recall and not laboratory con-
firmed, thus making it unreliable. Nevertheless, 
long- term treatment with fluconazole is not an 
effective treatment of vulvodynia. Candida can, 
however, be the initial aggression to the vestibu-
lar mucosa and it has been shown that in vulvo-
dynia patients the inflammatory response to it 
can be heightened [22].
Fig. 24.2 Vulvovaginal candidiasis (VVC), with vulvar 
erythema in the interlabial sulci Courtesy of Professor 
Jacob Bornstein




Clinical history and a vulvovaginal examination 
are fundamental parts of the diagnosis, but not suf-
ficient. Self-diagnosis of VVC is wrong in up to 
90% of cases and should not be encouraged [6, 23]. 
“Phone diagnosis” is also an unreliable approach.
The diagnosis is supported by wet mount 
microscopy (WMM), ideally using phase contrast 
microscopy [2] and, in some cases, by culture.
24.2.7.1  Microscopy
The most important tool in the diagnosis of VVC 
is microscopy, which should be performed sys-
tematically in women with suspected vulvovagi-
nitis. Not only it allows the diagnosis of VVC, 
as it is the only way to identify the presence of 
mixed infections. WMM is cheaper than Gram 
staining and allows an immediate diagnosis.
There is evidence that collecting the sample 
from the anterior vaginal wall increases the like-
lihood of identifying Candida [24].
Candida in WMM can present as mycelium 
and/or blastospores. Mycelium includes both 
hyphae (filaments that compose the body of the 
fungus) and pseudohyphae (filaments composed of 
elongated budding cells that failed to detach) and 
their presence is highly suggestive of infection, 
rather than mere colonization (Fig. 24.3). However, 
some species, like C. glabrata, are unable to form 
mycelium. The blastospores of C. glabrata tend to 
cluster and to have the shape of a bowling pin or a 
“snowman” (Fig. 24.4). In the presence of cluster-
ing blastospores, in the absence of mycelium, NAC 
should be considered (Fig. 24.5) [4].
Care must be taken not to confuse sperms 
heads with blastospores. The former tend to be 
asymmetrical (larger where the tail was attached) 
and are bicolor (Fig. 24.6) [4].
Some authors recommend the addition of a 
drop of KOH to the slide, which dissolves the 
epithelial cells and leukocytes, but not the fun-
gal structures, increasing the sensitivity of WMM 
to up to 85% [6, 24]. Other measures to try to 
improve the identification of these structures can 
include the staining with methylene blue [4].
The Pap test is specific for the presence of 
Candida, but has a sensitivity of only 25%, mak-
ing it useless as diagnostic tool. This comes as no 
surprise, since it is a cervical rather than a vaginal 
sample [6].
Fig. 24.3 C. albicans (pseudohyphae) in wet mount 
(phase contrast 400×). The background flora is nor-
mal, despite some scarcity of lactobacilli. (phase con-
trast, 400×)
Fig. 24.4 “Snowman” typical of C. glabrata (inside the 
white circle). Anaerobic type background flora (white 
arrows). (phase contrast, 400×)




Cultures are not needed routinely. Exceptions 
are recurrent episodes, microscopy negative or 
uncertain, or no response to treatment [2, 6]. 
Sensitivity tests are hardly ever needed, except 
for difficult NAC cases. C. albicans strains 
 resistant to fluconazole are uncommon and very 
rarely pose a clinical problem.
Identification of Candida in cultures, per 
se, cannot be assumed as a diagnosis of VVC, 
as it does not distinguish colonization from 
infection.
The swabs can be transported in common trans-
port means (Stuart or Amies)—or even without 
it, at room temperature, and should be cultivated 
within 6 h [4]. There seems to be no advantage 
between the available culture means (Sabouraud 
agar, Nickerson medium, or Microstix-Candida 
medium) for Candida [6].
24.2.7.3  pH
Candida is more often found with normal pH 
and is likely to be more symptomatic under those 
conditions. However, it may co-occur with BV or 
aerobic vaginitis (AV) (Fig. 24.4), which are typ-
ically associated with elevated pH. An elevated 
pH cannot rule out VVC, and at the same time, 
typical clinical presentation with a normal pH 
does not necessarily confirm the diagnosis [4].
However, the pH can guide the next steps in 
the management of the patient with symptoms 
suggestive of VVC: If microscopy is positive 
for Candida and the pH is increased, a mixed 
infection must be considered; if microscopy is 
negative and pH is normal, cultures are recom-
mended [6].
24.2.7.4  Molecular Tests
The Affirm VPIII is a commercially available 
test, based on DNA probes, that detects Candida, 
T. vaginalis, and G. vaginalis in vaginal samples, 
returning the result in 45 min. The sensitivity and 
specificity for Candida, in comparison with the 
gold standard (culture) were 82.76% and 98.80%, 
respectively [25, 26].
The use of nucleic acid amplification tests 
(NAAT) techniques increases the detection rate 
of Candida in 12.5% [27] and can be an option in 
those cases of high grade of suspicion, in which 
wet mount and cultures are negative. In recurrent 
cases, when microscopy is positive but cultures 
are negative, molecular techniques lead to the 
diagnosis of three times more cases [28, 29].
More recently, the BD MAX system, a real 
time PCR test for the detection of the presence 
of DNA from lactobacilli, bacteria associated 
Fig. 24.5 Clustering of blastospores, typical of NAC 
(white arrows). (phase contrast, 400×)
Fig. 24.6 Sperm heads, which can be mistaken by blas-
tospores (white arrows). Notice that these are bicolor and 
asymmetrical. (phase contrast, 400×)
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with BV, T. vaginalis, and Candida (C. albi-
cans, C. tropicalis, C. parapsilosis, C. dublini-
ensis, C. glabrata, and C. krusei) was developed. 
Sensitivity for the different species of Candida 
ranged from 75–91% and specificity was higher 
than 90%. It showed to perform similarly in self- 
collected samples [30].
These tests allow for faster results, are less 
operator dependent, and can improve the diag-
nostic performance, but pose the risk of overdi-
agnosis (not distinguishing colonization from 
infection), not recognizing the full picture (mixed 
infections), and are still expensive.
24.2.8  Treatment
24.2.8.1  General Principles
Since the symptoms are mostly vulvar, women 
must be warned that topical medication must 
be applied inside the vagina, rather than (just) 
in the vulva. External, vulvar application can 
lead to transitory relief of symptoms, but not 
to cure.
Topical antifungals can be oil based and, con-
sequently weaken condoms [10].
Oral azoles can interfere with oral anticoagu-
lants (increasing its levels) and anticonvulsants, 
such as phenytoin.
There is no indication to treat sexual partners, 
unless they have symptoms themselves (balani-
tis); in the latter case, topical antifungals can be 
used. Redness, in some cases, may be associated 
with an allergic reaction to Candida antigens, 
rather than infection.
Persistence of symptoms can be the result of 
a contact dermatitis, resulting from the repeated 
and long lasting treatments, or from secondary 
lichen simplex chronicus. In some cases, allergy 
to propylene glycol, a common excipient in vagi-
nal medications can develop.
24.2.8.2  Asymptomatic Candida
There is no reason to treat asymptomatic Candida 
in non-pregnant women, independently of being 
an incidental finding in a Pap test or other labora-
torial exam, or being suspected during a clinical 
examination.
24.2.8.3  Uncomplicated VVC
These cases should be treated with short courses 
(1–7  days) of vaginal imidazoles (clotrimazole, 
miconazole, butoconazole, etc.) or single doses of 
oral triazoles (fluconazole or, alternatively, itra-
conazole), which have similar efficacy (>80%) 
and adverse effects profiles [10] (Table  24.3). 
The choice for oral or topical routes is according 
to patients’ preferences. In some cases, women 
find a faster relief by using vaginal formulations, 
as it temporarily increases the pH.
There is no evidence that itraconazole is more 
effective than fluconazole [31, 32]. Topical poly-
enes, such as nystatin, have lower cure rates than 
topical imidazoles [33]. The limited data concern-
ing the use of terbinafine, an allylamine antifun-
gal suggests that it is efficacious if used topically, 
but not if orally [34, 35]. Data about ciclopirox 
olamine is also limited, but the few trials in which 
it was used showed it to be safe and effective.
24.2.8.4  Complicated VVC
Severe cases of VVC should be treated with more 
prolonged courses of topical antifungals or, if flu-
conazole is chosen, a second dose after 72 h is 
recommended (Table 24.3).
Topical, low potency corticosteroids (hydro-
cortisone) for a couple of days can be helpful in 
very symptomatic patients.
Cases of recurrent VVC are a truly clinical 
challenge. Reasonable attempts to control or cor-
rect risk factors should be tried: reducing sugar 
intake, stopping hormonal contraceptives or 
removing IUDs/LVG-IUSs, correcting excessive 
washing, stopping the use of tight or synthetic 
clothes, etc. Each measure should be sequen-
tially tried and, if not efficacious, suspended— 
otherwise, these changes will just add suffering to 
someone who already has an impaired quality of 
life due to a chronic disease [4, 6].
In case of failure of these measures, self- 
treatment of the episodes or, preferably, sup-
pressive treatment must be considered. The most 
commonly recommended treatment was proposed 
by Sobel [36] and consists of taking 150 mg of 
oral fluconazole weekly, for 6  months, after an 
induction in the first week (three times 150 mg in 
the first week). Donders proposed an alternative 
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Table 24.3 Treatment of VVC
Uncomplicated Topical (vaginal) Clotrimazole 1% cream 5 g id for 7–14 days
Clotrimazole 2% cream 5 g id for 3 days
Clotrimazole 100 mg suppository, id for 7 days
Clotrimazole 200 mg suppository, id for 3 days
Clotrimazole 500 mg suppository, single application
Miconazole 2% cream 5 g id for 7 days
Miconazole 4% cream 5 g id for 3 days
Miconazole 100 mg suppository, id for 7 days
Miconazole 200 mg suppository, id for 3 days
Miconazole 1200 mg suppository, single application
Tioconazole 6.5% ointment 5 g single application
Tioconazole 300 mg suppository, single application
Butoconazole 2% cream (bioadhesive), 5 g in a single application
Terconazole 0.4% cream 5 g id for 7 days
Terconazole 0.8% cream 5 g id for 3 days
Terconazole 80 mg suppository, id 3 days
Econazole 150 mg tablets, id for 3 days
Nystatin 100.000 units suppositories id for 14 days
Ciclopirox olamine 1% cream 6 days
Oral Fluconazole 150 mg, single dose
Itraconazole 200 mg id, 3 days
Itraconazole 200 mg 2 id, one day
Ketoconazole 200 mg 2 id, 5 days (hepatic toxicity)
Pregnancy Only topical azoles during 7 days
Breastfeeding Azoles excreted in milk; avoid during breastfeeding
Severe VVC Topical Prolong treatment for 7–14 days
Oral Fluconazole 150 mg day 1 and day 4
Recurrent VVC Fluconazole 
suppression for 
12 months (ReCiDiF)
Phase 1–200 mg po days 1, 4 and 7
Phase 2–200 mg po once a week for 2 months
Phase 3–200 mg po once every other week for 4 weeks
Phase 4–200 mg po once a month for 6 months










Intramuscular 150 mg every 12 weeks
Non-albicans 
VVC
Boric acid 600 mg 
vaginal capsules
Vaginally id for 2 weeks
Must be compounded by pharmacists
Toxic if per mouth
Maintenance regimen?





800 mg id for 2–3 weeks




 • Amphotericin B
 • Caspofungin
 • Micafungin
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regimen, after the ReCiDiF trial, lasting 1  year 
and consisting of progressively increased inter-
vals between fluconazole intake (see scheme in 
Table 24.3) [28]. In the later, while using the same 
total dosage of fluconazole and being comparable 
in terms of efficacy at 6 months, 77% of women 
were disease free at 12 months, comparing to only 
42.9% in the Sobel’s scheme [28, 36].
Episodes during suppressive therapy can be 
managed with topical antifungals; in occasional 
cases, antihistamines can be helpful.
Dennerstein reported good results in 
controlling the symptoms by using depo- 
medroxyprogesterone, probably by inducing a 
hypoestrogenic state [37]. In our hands, it has been 
an excellent option when other options fail.
It can be advisable that these patients have 
swabs with them, for self-collection and confir-
mation of the episodes.
In difficult cases, consider exclusion of HIV 
and diabetes.
In women with history of frequent or recur-
rent VVC after antibiotic intake, beta-lactamics, 
macrolides, and tetracyclines should be avoided. 
For urinary tract infections, alternative options 
include fosfomicine or norfloxacine. Additionally, 
prophylactic antifungals can be prescribed, to be 
taken at the beginning and halfway through the 
course of antibiotics [4].
The most common of the NACs, C. glabrata, 
is not sensible to the usual antifungals. One of 
the best alternatives is boric acid. Patients must 
be warned of its toxicity if ingested (gastrointes-
tinal, mental disorders, seizures, anaemia, etc.).
C. krusei is intrinsically resistant to oral tri-
azoles, however, it responds well to topical 
imidazoles, nystatin, boric acid, and ciclopirox 
olamine [2].
24.2.8.5  Candida in Pregnancy
Oral triazoles should not be used during preg-
nancy, as it has been related to spontaneous abor-
tion and to a slight increase in the risk of Fallot’s 
tetralogy.
As discussed previously, Candida can be asso-
ciated with negative obstetrical outcomes and for 
that reason some authors recommend treatment 
of asymptomatic women. This recommendation, 
however, is not universal and more data is needed 
to support it.
24.2.9  Future Perspectives
Despite the role played by lactobacilli in the 
prevention of symptomatic VVC, its administra-
tion either as treatment or adjuvant of antifungal 
treatment, has not shown to be useful in acute or 
recurrent episodes [38]. This line of investiga-
tion, however, can prove to have some role in the 
future, especially if strains that naturally domi-
nate the vagina of healthy women are used.
In the future, vaccines may be the answer to 
treat recurrent VVC.
24.2.10  Saccharomyces cerevisiae
The yeast S. cerevisiae can colonize the vagina of 
healthy women, and very rarely, become symp-
tomatic. Its incidence, however, seems to be ris-
ing and, apparently it is not always associated 
with professional exposure (brewery or bakery) 
or with consumption of it as a food additive or 
probiotic [39, 40].
Symptoms are undistinguishable from those 
of VVC. It is, however, less susceptible to anti-
fungals and is associated with high rates of recur-
rence. The diagnosis is confirmed by culture, 
but can be suspected when larger than usual 
blastospores are seen on WMM [4] (Fig. 24.7). 
Treatment options can include nystatin, ampho-
tericin B, flucytosine, and boric acid.
Fig. 24.7 Larger than usual budding blastospores (white 
arrows). Culture confirmed S. cerevisiae




24.3.1  Aetiology 
and Pathophysiology
Trichomoniasis is caused by the extracellular 
protozoan Trichomonas vaginalis, which was 
first described in 1836, but forgotten in the medi-
cal literature for a century.
T. vaginalis is of piriform, round or amoeboid 
shape, with a distinctive elongated nucleus, four 
anterior flagella, and a large posterior axostyle 
to which an undulant membrane is attached. It is 
motile, with fast and erratic movements.
The amitochondriate and anaerobic parasite is 
capable of phagocyting bacteria (including lac-
tobacilli), epithelial cells, and erythrocytes (from 
where it gets iron and cholesterol), but can itself 
be phagocyted by macrophages [41].
Its only natural hosts are humans, coloniz-
ing almost exclusively the genitourinary tract of 
both men and women. Infection sites in women 
include the vagina, endocervix, urethra, and para-
urethral glands. Very rarely it can be found in the 
respiratory tract.
In adults, transmission is almost exclusively 
by sexual route; direct vaginal or urethral inocu-
lation is needed. There are some reports of pos-
sible transmission by sharing the bath water, per 
fomites, or by genital manipulation by another 
infected person. The parasite can survive outside 
of the human body for periods of around 3 h, if 
protected from desiccation [42].
T. vaginalis can be infected by double strand 
RNA viruses, which, as discussed ahead, can 
have severe implications in its virulence [43].
24.3.2  Prevalence and Epidemiology
Trichomoniasis is the most common non-viral 
STI and prevalence seems to be rising [44, 45]. 
Existing projections are likely to be an underes-
timation of the true prevalence and burden of the 
infection, as it is not a reportable disease. This 
leaves extensive gaps in the understanding of the 
dynamics of the infection and the true extent of 
its complications.
Different diagnostic techniques and baseline 
characteristics of the populations studied pre-
clude comparisons between series. For instance, 
the very high prevalences found in STI clinics are 
unlikely to reflect the true picture for the general 
population [7].
According to World Health Organization, in 
2008, in the age range 15–49 years, trichomonia-
sis led the list of curable STIs, with 276.4 million 
of new cases in that year: more than the sum of 
those of Chlamydia trachomatis, Neisseria gon-
orrhoea and syphilis. The estimated number of 
T. vaginalis infections at any moment was esti-
mated at 187 million (Table 24.4).
The prevalence is much higher in females 
(5.6–22.0%) than in males (0.6–2.2%) 
(Table  24.4). Incidence, however, is similar in 
both sexes, ranging between 45.6 and 180.60/00 
(promil) [45], meaning that the rate of transmis-
Trichomoniasis: Breaking the Myths
• Trichomoniasis is not rare—it is the 
most common non-viral STI and preva-
lence seems to be rising.
• The classical image of the “strawberry 
cervix” is seen in less than 5% of the 
cases with T. vaginalis
• Maternal Trichomonas vaginalis infec-
tion is not only a nuisance. It is a risk 
factor for low birth weight, premature 
rupture of membrane, preterm labour, 
and even intellectual disability. One 
study related T. vaginalis with neonatal 
death.
Table 24.4 Prevalence and incidence of T. vaginalis in 
2008, according to the WHO. Adapted from Rowley et al. 
[45]
WHO region
Incidence (%0) Prevalence (%)
Female Male Female Male
African 146.0 164.8 20.2 2.0
Americas 177.7 180.6 22.0 2.2
South East-Asia 40.3 50.1 5.6 0.6
European 51.7 48.4 5.8 0.6
Eastern 
Mediterranean
64.0 66.1 8.0 0.8
Western Pacific 45.6 47.0 5.7 0.6
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sion and acquisition is similar, but males spon-
taneous eliminate the infection much faster. It 
usually takes about 10–21 days in males, while 
in women it can persist for months or even years 
[46]. However, in men it too can become chronic 
or reinfection can occur. The zinc rich milieu of 
prostatic secretions can account for these differ-
ences; chronic infection in men is more likely 
in those with lower concentrations of zinc in the 
prostatic secretions [47].
Transmission is more effective from males to 
female than the other way round (T. vaginalis is 
positive in 66–100% of the female partners of 
infected men vs. 30–80% of the male partners of 
infected women [48]).
The incubation period is believed to range 
between 4 and 28 days [49].
Contrary to other STIs, the prevalence of 
T. vaginalis, at least in some settings, peaks in 
women after 40  years of age. Possible expla-
nations include: (1) long-standing infection in 
reservoirs, such as the periurethral and subepi-
thelial glands, (2) increasing resistance to met-
ronidazole, (3) increased pH, due to the falling 
oestrogen levels, (4) sexual risk factors, and (5) 
screening artefact. The theory of sexual risk fac-
tors is supported by the fact that this peak was 
also described in men, and in women it only 
occurred in those who were also positive for 
high-risk human papillomavirus (HPV) [50].
24.3.3  Risk Factors and Associations
Despite geographical variations, racial, social, 
sexual, and behavioural factors for trichomonia-
sis have been identified, disentanglement of the 
various factors in order to distinguish true risk 
factors from mere associations is a nearly impos-
sible task.
In the United States, the prevalence of tricho-
moniasis in women of black race was four 
times higher than in the general population and, 
more striking, ten times higher than white non- 
Hispanic women.
In the same study, positive correlations were 
found with lower educational level, poverty, 
greater number of sexual partners, increasing 
age, and vaginal douching [51]. Other reported 
factors include early sexual debut, new or mul-
tiple sexual partners, having other STIs, incar-
ceration, commercial sex, being an immigrant, 
intravenous drug use, cigarette smoking, and not 
using condoms [51, 52].
Sexual factors, per se, cannot account for the 
full explanation of the different prevalences found 
in different countries: for instance, European 
countries with rates of Chlamydia similar to 
those found in the United States have lower rates 
of TV [41].
One interesting association is that of T. vag-
inalis with BV, which is found in 60–80% of 
cases. The mechanism is not fully understood: 
on one side, T. vaginalis benefits from the 
increased pH and anaerobic environment asso-
ciated with BV, and, on the other side, T. vagi-
nalis may disturb the vaginal microbiome and 
shift it to the anaerobic side [7].
24.3.4  Signs and Symptoms
It is estimated that up to 80–85% of infected 
women and 77% of men are asymptomatic [41, 
45, 48]. Many of the asymptomatic women even-
tually become symptomatic—sometimes in a 
very exuberant, highly symptomatic way. Given 
the long periods during which the infection can 
be asymptomatic, it is almost impossible to 
ascertain when infection was acquired.
When symptomatic, women can refer a yellow 
or green discharge, frequently with a foul smell. 
Urinary symptoms can be present (frequency, 
dysuria), as well as lower abdominal pain, dys-
pareunia, vulvar irritation, itching, and burning. 
Dysuria, unlikely in women with VVC is not 
only terminal or post-micturition, as there can be 
a real urethritis or cystitis (urethral involvement 
occurs in 90% of cases) [53]. Symptoms tend 
to worsen during menses, probably due to the 
increase in the number of parasites, associated 
with the phagocytosis of erythrocytes.
Some women may suffer from postcoital 
bleeding, as a consequence of the presence of 
erosions in the vaginal wall.
On physical examination, this discharge is 
frothy, more or less abundant and fluid (Fig. 24.8). 
Erosions, cervical friability, and vaginal enantema 
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can be noticed in the vaginal walls and the cervix. 
The classical image of the “strawberry cervix” is 
uncommon (<5%) (Fig. 24.9); after the applica-
tion of Lugol’s solution it may gain the typical 
appearance of “Leopard skin” (Fig. 24.10).
Very rarely, T. vaginalis can be associated 
with the enigmatic condition of emphysematous 
vaginitis, in which air bubbles form in the vagi-
nal walls, sometimes with crepitus during inter-
course or speculum examination [54].
A normal gynaecological examination is not 
sufficient to exclude the presence of T. vaginalis.
24.3.5  Complications
For a long time, T. vaginalis was considered a 
nuisance STI. However, nowadays, it is acknowl-
edged as being associated with severe complica-
tions, and considered a public health issue [41].
Maternal T. vaginalis infection is a risk factor 
for low birth weight (RR, 1.51; [95% confidence 
interval 1.32–1.73, p  <  0.001]), premature rup-
ture of membranes (RR, 1.41; [95% confidence 
interval, 1.10–1.82, p = 0.007]), preterm labour 
(RR 1.4 [95% confidence interval, 1.15–1.75; 
p = 0.001]) [55], and even intellectual disability 
[41]. One study related T. vaginalis with neonatal 
death (1.6% vs. 0.8%, p = 0.005) [56].
Fig. 24.8 Frothy vaginal discharge in a woman with 
Trichomonas vaginalis and bacterial vaginosis
Fig. 24.9 Strawberry cervix, typical of a Trichomonas 
infection
Fig. 24.10 Strawberry cervix after the application of 
iodine (“leopard skin”)
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T. vaginalis infected with M. hominis, besides 
being more cytopathogenic, induce an increased 
production of IL1β, IL6, IL8, and tumour necro-
sis factor (TNF) 1α—a similar profile to that 
associated with preterm labour [57].
Newborns from infected mothers can have 
a self-limiting vaginitis or pneumonia, but 
 sometimes treatment is required. The symptoms 
of vaginitis usually disappear as the levels of oes-
trogens wane.
T. vaginalis is a well-recognized risk fac-
tor for the transmission and acquisition of other 
STIs, namely HIV [58]. T. vaginalis increases the 
risk of acquisition and transmission by several 
ways: (1) by attracting inflammatory cells to the 
vagina, (2) by causing breaches in the integrity 
of the vagina and cervix (facilitating the access 
of HIV to the bloodstream), (3) by increasing 
IL-8, which increases HIV1 replication, and (4) 
by changing the vaginal flora towards BV [41].
Proper management of HIV patients should 
include regular screening of trichomoniasis (and 
BV), as it can be asymptomatic and still increase the 
HIV load in the vagina, as thus promote the transmis-
sion. Reducing T. vaginalis rates can be an effective, 
cost-effective measure to reduce HIV transmission, 
especially in populations such as in sub-Saharan 
Africa (Table 24.4), where it is believed to increase 
the risk of infection 2.1–2.8 times; this impact can 
be extensive to vertical transmission [59].
It has also been linked to increased risk of 
pelvic inflammatory disease, HSV2, persistence 
of HPV infection and cervical cancer, and false 
positive abnormal Pap tests [43, 44, 60]. Some 
authors claim it should be included in the carci-
nogenic agents list (increased risk of cervical and 
prostate cancer) [43].
T. vaginalis infections out of the genitouri-
nary tract are very rare, but a few cases have been 
described, including a central nervous infection 
in a premature neonate, leading to death [61].
24.3.6  Diagnosis
Given the burden of complications associ-
ated with T. vaginalis, low threshold for testing 
and sensitive tests should be used (Table 24.5). 
Table 24.5 Available tests for the diagnosis of T. vaginalis
Type of test Sensitivity Specificity Notes
Wet mount microscopy 36–82% 100%  •  Results in a few minutes
 • Easy and cheap
 • Low sensitivity
 •  Exam must be performed 
immediately
 • Not useful in men
Pap test 56–76%% >95%  •  Not recommended for 
screening
 •  Liquid based cytology 
performs better than 
classical cytology
 •  Controversial if further 









75–96% >95%%  • Not easily available
 •  Results in up to 7 days for 
diamond medium
 •  Vaginal secretions preferred
 •  In InPouch, most positive 
results occur within 3 days, 
but 17% only after that
 •  InPouch has increased 
sensitivity over traditional 
culture mediums (?)
 •  Useful if resistance tests are 
to be performed










82–95% >95%  • Results in 10–15 min
 •  Does not allow to test for 
other STIs
 • False positives possible
 •  Self-testing possible 
(decreased sensitivity) [62]
DNA probes Affirm VPIII 
(BD, Sparks, 
MD)
46.3–63% >95%  • Results in <1 h
 •  Concomitant test for C. 
albicans, G. vaginalis and 
T. vaginalis
 •  Useful in settings where 
STIs are not prevalent




>90% >95%  • Results in 45 min
 •  Good agreement with PCR




89.7% >95%  • Results in >45 min





>95% >95%  • Results in <8 h
 •  Possible cotest of CT/NG
 • FDA approved
In-house real 
time PCR
76–98% >95%  •  Better performance if 











 • Results in 60 min
 • FDA approved
BD ProbeTec Qx 
(BD, Sparks, 
Maryland)
>95% >99%  • Results in <8 h
 • FDA approved
BD MAX system 
(BD, Sparks, 
Maryland)
>90% >99% Results in 3 h
However, that is not the reality most of the times 
[63]. When comparing studies, it is important 
to keep in mind if the gold standard used was 
wet mount/cultures or the much more sensitive 
NAATs, as these can detect even non-viable pro-
tozoans and low loads of microorganisms.
Wet mount microscopy can allow the imme-
diate diagnosis, besides being a cheap and easy 
technique. However, it relies on documenting 
motile protozoans (https://www.youtube.com/
watch?v=pTL-_Q4S1Og). The observation 
should be performed immediately after collec-
tion of the sample; heating slightly the slide can 
increase the motility of the parasite. Immotile 
parasites are difficult to identify, as they have 
approximately the same size as a leucocyte. 
Inflammation is not always present (Fig. 24.11), 
but when present it can be very exuberant. Wet 
mount microscopy has a rather low sensitivity 
(36–82%) [64–67], even if using phase contrast 
and with experienced examiner. The sensitivity 
may be even lower in asymptomatic women, thus 
it cannot be recommended as a screening test. 
However, it can be used in a “cascade” model 
for symptomatic women: If it is diagnostic for 
T. vaginalis, treatment can be provided immedi-
ately; if negative, further laboratory testing must 
be carried out. Nevertheless, it is an excellent tool 
to check for the commonly associated presence 
of BV (Fig. 24.12).
Determination of pH is not a diagnostic tool, 
but it can work as a triage test; in symptomatic 
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trichomoniasis values are higher than 4.5 (fre-
quently even higher than 5) [42]. The sensitivity 
of pH for the diagnosis of trichomoniasis is very 
high, but the predictive positive value is very low.
The Whiff test is frequently positive, as the 
coexistence T. vaginalis and BV is very high 
(60–80%). However, a negative test does not 
exclude the diagnosis.
The Pap test should not be performed with the 
objective of diagnosing trichomoniasis. It is con-
troversial if the finding of T. vaginalis in a Pap 
test should be confirmed prior to treatment: Some 
defend that no further testing is needed if liquid 
based cytology was used (as specificity is high), 
while others only accept it in settings where the 
disease is very prevalent (>10%) [64], and oth-
ers recommend systematic confirmation [10]. If 
the diagnosis was made in a conventional Pap 
test, confirmation should always be performed 
prior to treatment. In one study from 1972, com-
paring Pap test to cultures for the diagnosis of 
trichomoniasis, it was concluded that the former 
yielded high rates of false negative and false 
positive results, making it highly unreliable. It 
was assumed that the source of mistake was the 
rounded forms that the protozoan can assume, 
and that are difficult to distinguish from leuko-
cytes [68].
Optimal tests for T. vaginalis in terms of sen-
sitivity are NAATs, which can detect 3–5 times 
more infections than WMM [10]. These tests, 
however, are expensive and do not produce an 
immediate result—which is of utmost impor-
tance in STI clinics.
Vaginal and endocervical specimens (swabs 
or liquid based cytology mediums) are the best 
sampling options. With the use of urine samples, 
sensitivity drops slightly [66].
In the future, versatile platforms such as the 
XPert T. vaginalis (Cepheid, Sunnyvale, CA) 
[69] can gain terrain in this field: The results are 
rapid (60 min) and the cartridge system allows the 
performance of different analysis using the same 
platform.
Point of care tests such as OSOM (Sekisui, 
Framingham, MA) or Affirm VPIII (BD, Sparks, 
MD) may represent an intermediate option, with 
a good performance, but cheaper than NAAT 
tests and allowing faster results, without the need 
for complex laboratory facilities.
24.3.7  Treatment
Treatment must be considered in all cases, as 
even if asymptomatic; T. vaginalis must not be 
seen as a commensal. The objectives of treating 
Fig. 24.12 Trichomonas vaginalis (white circle) and 
bacterial vaginosis (granular flora—black circle; clue 
cell—white arrow). Notice the presence of inflammation 
(black arrows), which is not a feature of BV (phase con-
trast, 400×)
Fig. 24.11 Trichomonas vaginalis (inside white circle) 
(phase contrast, 400×)
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all cases are: the elimination of symptoms, stop-
ping transmission, and reducing HIV risk.
As male partners of infected women have a 
high rate of infection [48], simultaneous treat-
ment of those partners without need for confir-
matory testing is mandatory.
The standard recommended treatment is a 
single dose of 2 g of metronidazole or tinidazole. 
Sexual abstinence for 1 week is recommended.
Patients must be advised to avoid alcohol con-
sumption, as a disulfiram effect is possible for up to 
24 h after taking metronidazole and 72 h after tini-
dazole; however, this risk may be overemphasized 
in the literature [70]. The most common second-
ary effects of nitroimidazoles are gastrointesti-
nal symptoms (nausea, vomiting, metallic taste), 
headache, and dizziness). These are dose depen-
dent and, for that reason, multi-dose schemes, are 
better tolerated. On the other hand, the compliance 
is higher for single dose schemes [71].
The success rate of cure with oral metroni-
dazole is high (>90%). Resistance, defined as a 
failure to eradicate the infection after two consec-
utive courses of treatment, is a raising problem, 
estimated to be of up to 5% [71]. For tinidazole 
it is lower (1%) [10]. Possible factors involved in 
resistance include: inactivation of metronidazole 
by vaginal bacteria, inadequate local concentra-
tion, and low zinc concentration [47]. It must 
be kept in mind, however, that many apparent 
failures of treatment are due to reinfection and 
non-compliance.
Zinc sulphate douches have been tried in small 
series, with good efficacy; however, it has been 
reported that it can cause cervical ulcerations 
[47] (Table 24.6).
Table 24.6 Treatment options for trichomoniasis
First choice Metronidazole  • 2 g per os, single dose
Tinidazole  • 2 g per os, single dose
 • Longer half-life
 • More expensive
 • Better intestinal tolerance
Alternative regimen Metronidazole  •  500 mg 2 id for 7 days (similar cure rates to 
single dose schemes)
 • Better tolerance
Metronidazole 750 mg/miconazole 
200 mg
 • Vaginal application 2 id for 7 days
 • Only if oral schemes not tolerated
 •  Very limited data on efficacy (one study)
In case of allergy to 
nitroimidazoles
Desensitization
Pregnancy Metronidazole  •  2 g per os, single dose (avoid higher doses in 
pregnancy)
 •  Consider multiple dose scheme if single dose 
not tolerated [71]
 • Treat all symptomatic cases
 •  If asymptomatic, consider treatment only in 
the first trimester or after 37 weeks of 
gestation
(Tinidazole)  • Avoid in the first trimester
 •  Use in the second or third trimester only if no 
better options available
Breastfeeding women Metronidazole  •  2 g per os, single dose (discard milk for 
12–24 h)
 • 500 mg 2 id per os 7 days
 • 400 mg 3 id per os 7 days
(Tinidazole)  • Avoid
 •  2 g per os, single dose (discard milk for 72 h)
HIV patients Metronidazole  • 500 mg 2 id for 7 days
(continued)
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The rate of clinical cure can be improved by 
using sensitivity tests and tailoring the treatment 
according to it (higher doses of metronidazole or 
changing to tinidazole).
Topical metronidazole is not recommended 
for treatment, as it is associated with very low 
rates of cure (<50%), probably due to the fact 
that only insufficient concentrations are achieved 
in the urethra and periurethral glands, which can 
act as reservoirs of the parasite. However, higher 
doses of vaginal metronidazole (750 mg), com-
bined with miconazole can lead to cure rates 
comparable to oral metronidazole [72].
It is still uncertain which is the impact of the 
coexistence of BV and T. vaginalis on the results 
of treatment, despite that both situations usually 
respond to nitroimidazole therapy [7].
Treatment during pregnancy, in one study 
increased the risk of preterm delivery three times 
(RR 3.0; 95% confidence interval, 1.5–5.9) but 
this is still controversial and not confirmed in 
other studies [73, 74]. One of the theories sustains 
that the exposition of T. vaginalis infected with M. 
hominis to antibiotics leads to a massive release 
of the latter. These, once released, can infect the 
membranes and the amniotic fluid, thus initiating a 
preterm labour [73]. Treatment, however, reduces 
the risk of transmission to the newborn and 
decreases the risk of HIV infection. One reason-
able option is treating all cases in the first trimester 
(to reduce HIV risk), the symptomatic cases at any 
time, and the asymptomatic ones after 37 weeks of 
gestational age (to reduce the risk of transmission, 
without increasing that of preterm labour) [53].
Women who test positive for T. vagina-
lis during pregnancy should be counselled to 
consistently use condoms, besides the adequate 
treatment of all sexual partners.
A test of cure can be performed 2–3  weeks 
after the treatment; prior to that, NAATs can be 
positive due to the presence of non-viable organ-
isms. In pregnant women, given that T. vaginalis 
is a risk factor for HIV, the CDC recommends 
retesting after 3 months. In HIV women, retest-
ing is also recommended [10].
24.4  Dysbiosis
Vaginal dysbiosis refers to the conditions in which 
there is a flora disturbance or imbalance, charac-
terized by a severe depletion or even absence of 
lactobacilli [75]. Traditionally, it has been assumed 
that BV is “the” cause for absent lactobacilli in 
non-hypoestrogenic women. However, clinical 
practice, especially with the use of WMM, has 
shown that it is not necessarily true. An increased 
pH (a marker of lactobacilli depletion and, thus, 
dysbiosis) is found not only in BV, but also in con-
Vaginal Lactobacilli: Breaking the Myths
• Bacterial vaginosis is not the only 
cause for absent lactobacilli in non- 
hypoestrogenic women. Aerobic vagi-
nitis is another cause, which is much 
less recognized
• Despite the important role of Lactobacilli 
in vaginal health, they are absent in 
nearly one third of asymptomatic women
Alternative treatments in 
resistant cases (always 
consider non-compliance 
or reinfection)
Metronidazole  • 800 mg 3 id for 5–7 days
 •  2 g id for 5–7 days ± intravaginal tinidazole
Tinidazole  • 2 g id per os for 5–7 days
 •  2–3 g id per os for 14 days (same for partners)
Options needing further studies:
 • Zinc sulphate 1% (± oral tinidazole) douches
 • Pessaries (paromomycin/furazolidone/6% non-oxynol-9)
 • Boric acid (vaginal)
 • Disulfiram
 • Nithiamide
 • Albendazole + nitroimidazole
 • Coenzyme B12 + nitroimidazole
Table 24.6 (continued)
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ditions in which aerobic, rather than anaerobic, 
bacteria predominate. Besides the overgrowth of 
aerobic bacteria, these women usually also have 
atrophy and inflammation (which are not part of 
BV) [76]. This entity was named aerobic vaginitis 
(AV) by Donders et al. in 2002 [77].
The non-recognition of AV may have led to seri-
ous drawbacks in clinical investigation, namely in 
the areas of preterm labour, sexually transmitted 
infections, and cervical dysplasia [78].
The concept of the essential role of the domi-
nance of lactobacilli in the vaginal flora during 
reproductive age has been challenged, as it has 
been shown that it does not happen in nearly one 
third of asymptomatic women [79]. This is the 
rule in other species of mammals, in which lacto-
bacilli represent only 1% of the vaginal microbi-
ota, while one similar to that associated with BV 
dominates (Gardnerella, Mobiluncus, Sneathia, 
and Prevotella). Bacteriocins are not of exclusive 
production by lactobacilli; other bacteria such as 
Streptococcus, Prevotella, and Corynebacterium 
may fulfil that function [80].
24.4.1  Bacterial Vaginosis
Some authors have suggested that the condition 
should be named anaerobic vaginosis, rather than 
bacterial, as it overemphasizes a mere bacterial 
aetiology [81].
24.4.1.1  Aetiology 
and Pathophysiology
BV is a polymicrobial syndrome, characterized 
by the absence of lactobacilli and overgrowth of a 
variable mixture of predominantly anaerobic and 
facultative bacteria, which in low loads are part 
of the normal vaginal flora. These can include 
G. vaginalis, Atopobium vaginalis, Mobiluncus, 
Prevotella, Megasphaera, Leptotrichia, Sneathia, 
Bifidobacterium, Dialister, Peptostreptococcus, 
Fusobacterium, Clostridium, non-cultivable 
“BV-associated bacteria” (BVAB) 1–3, and M. 
hominis, among others, in loads 100–1000 times 
higher than the normal. Identifiable modifica-
tions in the microbiota precede the development 
of BV by weeks or months [82].
Given that these bacteria are sensitive to lactic 
acid and hydrogen peroxide, the initial step for the 
development of BV is likely to be the reduction or 
disappearance of lactobacilli. Several endogenous 
and exogenous factors, including phages and some 
Mollicutes, can be responsible for this [81, 83].
According to the model proposed by 
Nasioudis et al., it all starts with a transitory state 
of diminished lactobacillary dominance. During 
this stage, if the disturbing factor is enough to 
prevent the recovery of the lactobacilli or gives 
advantage to other bacteria in the competition for 
glycogen, a biofilm starts to be produced. The 
biofilm further deprives lactobacilli from having 
access to manganese, inhibiting their recovery, 
and allows the eviction of the already depressed 
innate immune system defences (low levels of 
H2O2 and lactic acid) [58, 84]. Additionally, the 
production of sialidase leads to the degradation 
of IgA, impairing the acquired immune system 
response. The immunological response is typi-
cally absent or scarce [58, 84].
24.4.1.2  Prevalence 
and Epidemiology
BV is the most common cause of symptom-
atic vulvovaginal discharge in childbearing age 
women, accounting for nearly half of the cases. 
It is rarely encountered in children and becomes 
less common during menopause. Prevalence is 
lower during pregnancy [85].
As BV is asymptomatic in 50–85% of the 
cases, when comparing epidemiological data, 
it must be checked whether it refers to micro-
biological or clinical (symptomatic) disease and 
how the diagnosis was established.
Bacterial Vaginosis (BV): Breaking the Myths
• BV may go unnoticed—it is asymptom-
atic in 50–85% of the cases
• BV is a sexually associated condition but 
not an STI, as no disease has been identi-
fied in the male partners, the condition 
cannot be attributed to a single microor-
ganism, and treatment of the partner 
does not prevent recurrences in women.
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Global prevalence (symptomatic and asymp-
tomatic) varies widely according to the popula-
tion studied (12–55%), being consistently higher 
in black women (50–55%) [86, 87]. BV is much 
rarer in non-sexually experienced women, espe-
cially in those without any kind of sexual contact 
[88], but is very high (20–50%) in women with 
female partners [89].
24.4.1.3  Risk Factors 
and Associations
BV is a sexually associated condition (Table 24.7). 
It cannot be considered an STI, as no disease has 
been identified in the male partners, the condi-
tion cannot be attributed to a single microorgan-
ism, and treatment of the partner does not prevent 
recurrences in women. However, there is a grow-
ing evidence that BVAB can be exchanged dur-
ing intercourse, and it has been isolated from the 
penis, seminal fluid, and even urine of male part-
ners of women with BV. The bladder may act as a 
reservoir for recurrences [90]. Circumcision can 
decrease the load of BVAB and, consequently the 
risk of BV in partners [91].
While women usually do not consider it an 
STI themselves, they can link sexual activity to 
the development or recurrence of symptoms [92].
Phages can be the “missing link” between BV 
and its association with sexual activity: hypo-
thetically, a partner may transmit it, leading to 
the depletion of lactobacilli [81]. Interestingly, 
phages are promoted by smoking, which is also 
a risk factor for BV, by direct toxicity to lacto-
bacilli, and by inducing hormonal changes [93].
While L. crispatus is associated with a lower 
risk for BV, L. iners can be identified during dys-
biosis. It is uncertain whether it predisposes to 
dysbiosis or is part of the recovery process [82, 
94]. Interestingly, female couples share lactoba-
cilli strains [95].
Progesterone seems to play a protective role, 
as the rates of BV are lower and the cure rates 
higher during pregnancy, and less cases are 
detected during the luteal phase [96].
24.4.1.4  Signs and Symptoms
More than half of the women with BV type flora 
are asymptomatic. If not, symptoms tend to be 
mild, fluctuating and sometimes with a long- 
standing duration (weeks or months).
The most common symptom is an offensive 
fishy smell, which typically worsens with menses 
and sexual intercourse, as the release of volatile 
amines (putrescine and cadaverine) is increased 
in elevated pH. Sometimes women tend to wash 
more frequently or to use perfumed products, 
which paradoxically further worsen the smell.
The discharge associated with BV is yellow 
or grey, homogeneous, thin, and adherent to the 
vaginal walls (Fig. 24.13a). Mild burning or dys-
uria are sometimes described, but are not typical 
features of BV.
The vulvar and vaginal exam, apart from the 
presence of discharge, are usually unremarkable 
(Fig. 24.13b).
BV can be considered recurrent if a woman 
has 3 or more episodes during 1 year.
24.4.1.5  Complications
The risk of complications is independent of 
whether or not a woman is symptomatic.
Table 24.7 Risk factors and associations for BV
Demographic 
factors
 • Lower educational level
 • Poverty
 • Black race
 • Childbearing age
Sexual factors  • New partner(s)
 • Multiple partner(s)
 •  Higher number of lifetime sexual 
partners
 • Having female partner(s)
 • Receptive oral sex
 • Anal sex
 •  Higher frequency of intercourse
 • Early sexual debut
 • Unprotected sex




 • Vaginal douching
 • IUD
 • Not using oral contraceptives
 •  Having an STI (HIV, HSV2, C. 
trachomatis, M. genitalium)
 • Uncircumcised partner
 • Antibiotic use
 • Stress
 •  Dietary factors (increased fat, low 
calcium, folate, and vitamin A)
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Most studies failed to distinguish BV from 
AV, as the diagnosis was frequently based on an 
increased pH and/or absence of lactobacilli. This 
can explain different results between studies and 
why, for instance, treatment failed to reduce the 
risk of preterm labour in women with the diag-
nosis of BV. The listed complications most likely 
represent those of abnormal vaginal flora or dys-
biosis, rather than just of BV.
BV was first associated with adverse preg-
nancy outcomes in 1984, namely with preterm 
labour. Following that, other obstetrical and neo-
natal complications were added to the list: spon-
taneous abortion, low birth weight and increased 
neonatal morbidity [97].
Pelvic inflammatory disease, post- 
hysterectomy cuff infection and post C-section 
endometritis are also more common in women 
with BV.  Interestingly, there are theories sus-
taining that one of the roles of vaginal lactoba-
cilli may be the reduction of the infectious risks 
related to pregnancy and delivery [80].
The risk of acquiring an STI, including C. 
trachomatis, N. gonorrhoea, HSV2 and HIV 
infection, is double in women with BV [98]. U. 
urealyticum, U. parvum and M. hominis, but not 
M. genitalium, are frequently found associated 
with BV [99].
Additionally, it increases the risk of trans-
mission of HIV to male partners [100]. Several 
a b
c
Fig. 24.13 (a) Homogenous vaginal discharge in a 
woman with bacterial vaginosis. (b) At the vulva, the 
homogenous vaginal discharge can be easily detected 
in women with bacterial vaginosis. (c) Bacterial vagi-
nosis with all typical features: no lactobacilli, granular 
floor (white circle) and clue cells (white arrows) (phase 
contrast, 400×)
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studies link BV to HPV persistence, cervical dys-
plasia and cancer.
More recently, there is increasing data relat-
ing BV with infertility and lower success rates of 
assisted reproduction techniques [101].
24.4.1.6  Diagnosis
BV should not be screened in asymptomatic 
women; it can be considered, but without enough 
evidence to recommend it, in pregnant women, 
prior to pelvic surgery or uterine cavity instru-
mentation, or in those with STIs, especially HIV.
Clinical Diagnosis
Clinical criteria allow the diagnosis of BV in set-
tings of limited resources or expertise. To fulfil 
the Amsel criteria [102], 3 out of the following 4 
must be fulfilled:
 1. Homogeneous grey or white discharge coat-
ing the vaginal walls (Fig. 24.13a, b);
 2. Vaginal pH increased (>4.5);
 3. Fishy smell (before or after 10% KOH addi-
tion—Whiff test);
 4. Clue cells on wet mount (cells with a heavy 
coating of bacteria, leading to blurring of the 
peripheral borders; must be present in >20% 
of cells) (Fig. 24.13c).
The sensitivity and specificity of the Amsel 
criteria is around 80 and 90%, respectively. The 
first three criteria are also frequently positive in 
women with trichomoniasis. The combination of 
only pH and Whiff test may perform better than 
the traditional criteria [103]. However, odour 
is too subjective to base a diagnosis on; in the 
future, it may be overcome by the use of “elec-
tronic noses” [104].
In our opinion, in settings where a micro-
scope is available, it should be used for the 
proper diagnosis of BV by WMM, rather than 
just for the mere evaluation of the presence of 
clue cells.
pH
The pH based point of care tests available for 
self-testing have a sensitivity and specificity of 
73% and 67%, respectively [105].
The VI-SENSE is a pH test, based on a strip 
placed in a panty liner; clinical trials showed 
good performance for BV or trichomoniasis, but 
not allowing distinction between both conditions 
[106].
Microscopy
In WMM, BV is characterized by absent lacto-
bacilli, granular flora or abundant motile small, 
curved, rod shaped bacteria (Mobiluncus), 
absence of inflammation, and presence of clue 
cells (Fig. 24.13c).
WMM has several advantages relatively 
to Gram staining based Nugent score: (1) it is 
cheaper, (2) allows the diagnosis during the 
appointment, (3) requires less expertise, (4) 
allows the distinction of full-blown from partial 
BV (in which in the same slide areas of granu-
lar flora can coexist with areas with lactobacilli, 
and frequently clue cells represent <20% of the 
total number of epithelial cells) and the over-
come of the problem of “intermediate scores” 
from Nugent score, and (5) the evaluation of the 
bacteria may be more accurate, since there is no 
fixation and washing of the slides.
The Nugent score, an improvement from the 
Spiegel score, was described in 1991 [107], and 
is considered the gold standard for the diagnosis 
of BV. It is based on the proportion of bacterial 
morphotypes, using Gram staining:
 – Lactobacilli (large Gram-positive rods)—0 to 
4 points (higher scores if less abundant);
 – G. vaginalis and bacteroides (small Gram 
variable rods)—0 to 4 points (higher scores if 
more abundant;
 – Mobiluncus-like morphotypes (curved Gram 
negative rods)—0 to 2 points (higher scores if 
more abundant);
 – (Gram-positive cocci are not considered in 
this scoring system).
The diagnosis of BV is established if the final 
score is equal or higher than seven. If it is equal 
or lower than three, it is considered normal. A 
score between 4 and 6 is the troublesome “inter-
mediate score”. It does not correspond to partial 
BV; part of the cases classified in this grey area, 
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which usually do not respond to metronidazole 
treatment, may represent AV.  For this reason, 
Donders proposed that “undetermined flora” 
would be a more accurate description [108].
The Hay and Ison criteria [109], also based on 
Gram staining may allow a more complete and 
realistic evaluation of the vaginal flora:
 – Grade 0—epithelial cells with no bacteria seen;
 – Grade I—lactobacillus morphotypes only 
(normal flora);
 – Grade II—reduced lactobacillus morphotypes 
with mixed bacterial morphotypes (intermedi-
ate flora);
 – Grade III—mixed bacterial morphotypes with 
few or absent lactobacillus morphotypes (BV);
 – Grade IV—epithelial cells covered with 
Gram-positive cocci only (AV type flora).
Cultures
G. vaginalis can be cultivated from the large 
majority of women with BV, but also from more 
than half of the women without it [110]. This 
translates into a high sensitivity, but a low posi-
tive predictive value and thus should not be used.
Pap Test
The Pap test is not intended for the diagnosis of 
vaginitis. The sensitivity for BV is low, and likely 
to be even lower when using liquid based cytology, 
due to centrifugation and filtering of the sample.
Enzymatic Tests
The OSOM BVBlue is a point of care test, based 
on the chromogenic determination of the presence 
of sialidase, which is produced by bacteria com-
monly involved in BV (Gardnerella, Prevotella 
and Bacteroides). The results are available within 
10 min. The sensitivity of the test is variable (38–
100%), while the specificity is systematically high 
(>90%) [111]. In AV, sialidase is also increased 
and it may explain part of the differences in sensi-
tivity across studies.
Tests to evaluate the activity of proline ami-
nopeptidase have also been designed, giving the 
results in 10 min. Sensitivity and specificity are 
higher than 90% [112]. It has also been evaluated 
in combination with pH and amines determina-
tion (FemExam).
Molecular Tests
The use of DNA tests in BV is very complex, as 
it is polymicrobial and most of the involved agents 
commonly colonize the vagina of healthy women in 
low loads. These techniques are usually highly sen-
sitive, but with low predictive positive values. In the 
future, combinations of evaluation of the proportion 
of selected anaerobic bacteria and lactobacilli may 
increase the specificity of this methodology [113].
Nevertheless, the Affirm VPIII, which tests not 
only BV, but also T. vaginalis and Candida, has 
been shown to be a good alternative in settings 
where a microscope is not available [25, 26].
24.4.1.7  Treatment
BV can heal spontaneously [53]. Treatment 
aims at resolving the symptoms associated with 
BV; there is no indication to treat asymptomatic 
women. It can, however, be considered in high- 
risk populations for STIs, as it can reduce the risk 
of acquiring HIV, T. vaginalis, C. trachomatis, N. 
gonorrhoea and HSV2, and before pelvic surgery.
Therapeutic options for BV include oral and 
topical antibiotics (metronidazole, tinidazole 
and clindamycin), and antiseptics (dequalinium 
 chloride) (Table  24.8). The rates of cure are 
high for all drugs and routes (around 80%), but 
relapses are common [10, 114].
The vaginal levels achieved with topical medi-
cation can be 30 times higher than those achieved 
with oral medication. This translates into cure 
rates equal or slightly higher than those achieved 
with the oral route, with the advantage of having 
less adverse effects. Combinations of oral and 
vaginal treatment can increase the cure rates [115].
Despite the perceived increased resistance to 
metronidazole and clindamycin, it does not seem 
yet to be a major clinical issue [85, 116]. Some 
Gardnerella strains have been shown to be intrin-
sically resistant to metronidazole [117]. Several 
of the bacteria involved in BV cannot be culti-
vated, thus making it impossible to test its sus-
ceptibility profiles.
The cure rates achieved with the antiseptic 
dequalinium chloride are non-inferior to those of 
clindamycin [116]. It has the advantages of being 
less toxic for lactobacilli, and not increasing 
the risk of VVC, contrarily to antibiotics [118]. 
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Additionally, it is not expected that bacteria 
develop resistance to it and can have some effect 
in other causes of “vaginitis” other than BV, 
thus making it at least partially useful for mixed 
infections, including AV, VVC and trichomonia-
sis [116]. However, long-term studies concerning 
recurrences are still lacking.
Women must be warned about the possible 
interaction between alcohol and nitroimidazoles. 
Clindamycin is associated with pseudomem-
branous colitis, and topical formulations may 
weaken latex condoms.
The use of H2O2 irrigations has resulted in con-
tradictory results, but it seems to be less effective 
than metronidazole, and associated with a risk 
of development of severe lesions in the vaginal 
mucosa, due to its caustic effects [119].
The use of acidifying agents, though tempt-
ing, has not proven to be efficacious. Only the use 
of ascorbic acid has some clinical support [120].
There is no evidence that the use of probiotics 
in acute episodes, isolated or concomitantly with 
antibiotics improves the rate of success [121].
Pregnancy
Treatment of BV during pregnancy with metro-
nidazole failed to decrease the risk of preterm 
labour and, in some studies, even lead to an 
increase. On the contrary, in most  series in which 
clindamycin was used showed a decrease in the 
rate of preterm labour [122–124]. Difference in 
terms of outcomes may be related to the antibiot-
ics spectrum: clindamycin covers Gram-positive 
bacteria, frequently involved in AV. New studies 
with a more accurate classification of the vaginal 
flora may settle the question in the near future.
While treatment of symptomatic women dur-
ing pregnancy is recommended, the available data 
does not allow the recommendation of screening 
and treating asymptomatic cases.
All first line schemes recommended for non- 
pregnant women can safely be used during all 
trimesters of pregnancy. There was some concern 
about the use of clindamycin during the second 
half of pregnancy, but it has been shown that 
there is no reason for that [10, 53, 125].
Recurrent BV
Antibiotic treatment is usually effective, but 
relapses are common, estimated at 50–70% at 
6–12  months [126]. There is contradictory data 
associating A. vaginae and specific strains of G. 
vaginalis with failure of treatment and recurrences 
[85, 127, 128]. Bacterial strains that produce more 
sialidase have a higher potential of developing 
a biofilm and adhering to epithelial cells [129]. 
Table 24.8 Treatment of BV
First line Metronidazole tablets 500 mg per os 2 id 7 days
Metronidazole gel 0.75% 5 g id intravaginally 5 days
Clindamycin cream 2% 5 g id intravaginally 7 days
Dequalinium chloride 10 mg tablets id intravaginally 6 days
Second line Tinidazole 2 g id 2 days
Tinidazole 1 g id 5 days
Clindamycin 300 mg per os 2 id 7 days
Clindamycin 100 mg vaginal ovules id for 3 days
Alternatives Secnidazole 2 g per os, single dose
Polyhexamethylene biguanide 
hydrochloride
1–2 id for 7 days
Chlorhexidine Vaginal douche once a day
Rifaximin 25–100 mg id intravaginally
Recurrent 
BV
Metronidazole 0.75% gel 2 times/week for 4–6 months
Triple phase regimen: Oral 
nitroimidazole, vaginal boric acid, 
and vaginal metronidazole
 • Oral nitroimidazole for 7 days
 • Vaginal boric acid for 3 weeks




Ascorbic acid 250 mg vaginal tablets id 6 days/month for 6 months
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Higher loads of bacteria also seem to correlate 
with an increased risk of recurrence [130].
Recurrent episodes can be managed by using 
a different antibiotic/antiseptic from the previ-
ous episode, for a longer duration. The use of 
repeated options in the subsequent episodes is an 
acceptable approach [131].
Some patients will opt for a suppressive 
treatment. The use of metronidazole 0.75% gel 
twice a week for 4–6 months is one of the most 
commonly used regimens, with an efficacy of 
70%. However, the rate of relapse severely 
increases once it is stopped and VVC is not 
uncommon during treatment (43.1%) [132]. A 
regimen in which 2 g of oral metronidazole and 
150 mg of oral fluconazole monthly was used, 
in HIV1 women showed to be effective, and the 
risk of VVC was lower than in the placebo arm 
[133].
There is no advantage in the treatment of 
male partners, however this recommendation is 
not based on good quality studies [10, 134]. If 
the phages theory proves to be correct, the male 
treatment will not be effective indeed.
Using oral contraceptives continuously for 
3 months is a strategy that can be tried; it may 
work both by reducing the levels of oestrogens 
and by eliminating the exposure to blood [85].
A triple sequential scheme, including oral 
metronidazole or tinidazole, vaginal boric acid, 
and vaginal metronidazole, has shown a cure rate 
of 65% at 28 weeks, but it has a failure rate of 
50% at 36 weeks [135].
Recurrences/treatment failures seem to be asso-
ciated with inability to eradicate the biofilm. Boric 
acid is one of the agents capable of destroying it; 
other options may include tobramycin, DNases, 
octenidine, and retrocyclin, among others [98].
The concept of using probiotics to restore the 
vaginal health is intuitive and appealing, however 
the studies have not supported its use. It does not 
seem to affect the cure rate, but may increase the 
time to recurrence in 50% [136, 137]. Failure to 
improve the vaginal flora with probiotics may be 
due to the use of inadequate species (the ones 
commercially available usually are not dominant 
ones in healthy women) and/or inability to colo-
nize the vagina.
There is no data supporting the use of acidi-
fiers of the vagina for the purpose of avoiding 
recurrences [138].
Future options may include oral or vaginal 
lactoferrin, which can act by immunomodulation, 
disruption of the cell membranes, and by binding 
to iron and thus making it unavailable for bacte-
ria (without affecting lactobacilli, which rely on 
manganese for their metabolism) [126].
24.4.2  Aerobic Vaginitis, 
Desquamative Inflammatory 
Vaginitis, GBS Vaginitis
In 2002, Donders et al. named a condition charac-
terized by lack of lactobacilli, presence of aerobic 
(enteric) bacteria, and atrophy as aerobic vagini-
tis, thus stressing the main differences between 
this entity and its anaerobic, non- inflammatory, 
counterpart: BV [77]. Its most severe forms of 
presentation correspond to the desquamative 
inflammatory vaginitis (DIV), described by 
Gardner in 1968 [139] (probably the same as 
Scheffey’s “exudative vaginitis” [140]). While 
DIV is an extreme form of the disease, AV shows 
the full spectrum of the disease [141].
Group B streptococcus (GBS) vaginitis is also 
included in the spectrum of AV.  GBS is today 
considered one of the agents commonly found in 
women with AV.
Even though it is more and more recognized 
as a nosologic entity, unfortunately it still is 
not the rule. Failure to recognize it may be a 
missed opportunity to help women with other-
wise “untreatable” or “unspecific” vaginitis, and 
to diminish the associated gynaecological and 
obstetrical risks associated with it.
As we consider these entities as subtypes of 
AV, AV will be used to discuss it as a whole.
Aerobic Vaginitis: Breaking the Myth
• Group B streptococcus (GBS) infection 
and desquamative inflammatory vagini-
tis (DIV) are not separate entities. They 
are a part of aerobic vaginitis (AV).




The aetiology of AV remains unknown. Although 
the isolation of bacteria other than lactobacilli is 
one of the features of AV, it cannot be assumed 
straightforward that AV is an infection—its pres-
ence may be secondary to the abnormal local 
conditions. The most commonly isolated bacteria 
are Streptococcus spp., S. aureus, coagulase neg-
ative staphylococci, E. coli and E. faecalis [142].
The lack of lactobacilli, namely the H2O2 pro-
ducing strains which are capable of reducing the 
levels of IL-1β [143] can, partially, explain the 
inflammatory response found in AV.
Host immunity factors can also be involved, 
as not only the levels of IL-1β are increased 
(higher than in women with BV), but also those 
of IL-6 and -8 (while in BV they are within nor-
mal range) [144, 145]. Sialidase, which leads to 
diminished local immunity by ultimately caus-
ing IgA proteolysis, is increased in both AV and 
BV [144].
The presence of intermediate or even para-
basal cells suggests a role for hypoestrogenism. 
However, it must be a local phenomenon, given 
that it can be seen in women without further evi-
dence of low oestrogens, and systemic treatment 
is ineffective.
Other theories include that AV/DIV might be 
localized forms of lichen planus, or that it is a 
consequence of low levels of vitamin D [142].
24.4.2.2  Prevalence 
and Epidemiology
Data concerning the epidemiology of AV is 
still scarce, however we are starting to see the 
broad picture. Comparing data on prevalence is 
not easy, as studies considered different grades 
of AV, some looked only into symptomatic 
women, and others considered only pregnant 
women.
In Europe, the prevalence rate of moderate or 
severe AV (msAV) seems to range between 7.4 and 
12.0%, while it seems to be less common in South 
America (2.0–2.9%), and more common in Africa 
(11.0–25.8%) [142]. The prevalence is systemati-
cally lower in pregnant women (4.0–8.0%) [57], 
and in one study it has been shown to be very high 
in a cohort of 123 HIV positive women (26.8% 
with msAV and 20.4% with light forms) [146].
It can be found in women of all ages (not stud-
ied in children), but there seems to exist a peak in 
the peri-menopausal period.
24.4.2.3  Risk Factors 
and Associations
Up to the moment, the studies concerning risk 
factors and associations with AV are very limited. 
One Chinese study associated AV with being 
unmarried, using an IUD, long-term use of anti-
biotics, and vaginal douching; on the contrary, 
higher education and systematic use of condoms 
were protective [147]. The latter was not con-
firmed in a European study [78].
24.4.2.4  Signs and Symptoms
AV can range from asymptomatic to highly 
symptomatic. Symptoms can include yellow-
ish or yellow-green vaginal purulent discharge 
(in 20% with a rotten smell—different from the 
fishy one typical of BV), dyspareunia, burning 
and stinging. The vagina and the vestibule can be 
reddish and with erosions (Fig. 24.14) [57, 77]. 
Symptoms can be present for months with vari-
able intensity [142].
Fig. 24.14 Erosions of the vaginal walls in a patient with 
severe aerobic vaginosis




The number of studies linking AV with severe 
gynaecological and obstetrical complications has 
been growing the last years [142].
Among gynaecological complications, there 
are studies relating it to an increased risk of hav-
ing an abnormal Pap test and of acquiring STIs. 
The presence of inflammation and erosions, the 
lack of lactobacilli, and the associated increased 
levels of sialidase can easily explain the increased 
risk for STIs; diagnosing and treating AV can be 
highly relevant in populations at elevated risk, 
namely in Africa [87, 118].
In terms of obstetrics, it can be the explanation 
for the contradictory results found when relating 
flora changes to preterm labour. It has also been 
linked to premature rupture of membranes, cho-
rioamnionitis and even neonatal sepsis.
The interleukin profile associated with these 
complications, as well as that associated with 
cervical intraepithelial neoplasia and cervical 
cancer are near perfect matches with that of AV 
[78, 142, 148].
24.4.2.6  Diagnosis
The diagnosis of AV is made with the aid of 
a microscope, ideally with phase contrast 
(Fig.  24.15). A composite score must be calcu-
lated, including: (1) relative quantity of lactoba-
cilli; (2) presence of inflammation; (3) relative 
quantity of toxic leucocytes (active, swollen leu-
cocytes); (4) presence of other bacteria and (5) 
proportion of parabasal cells (Table 24.9). WMM 
is a better tool than Gram staining, as the former 
allows a more precise evaluation of the lacto-
bacillary grades.
Cultures are not useful, as it is not informa-
tive of the relative proportion of lactobacilli 
and other bacteria and colonization is common 
[113].
The pH is usually increased, in a more pro-
nounced way than in BV [149].
Rumyantseva et al. have shown that molecu-
lar diagnosis, using real time PCR is feasible 
and, in the future, can be an option in settings 
where health care professionals are not trained 
to perform microscopy [113]. Enzymatic test 
has already been developed, but validation is still 
needed [150].
Fig. 24.15 Severe aerobic vaginosis/desquamative 
inflammatory vaginitis: absent lactobacilli, basal/para-
basal cells (white arrows), cocci (white circle), and 
inflammation (black arrows) (phase contrast 400×)








0 I or IIa ≤10 per HPF Absent Unremarkable or 
cytolysis
<1%
1 IIb >10 per HPFand 
≤10 per cell
≤50% Small coliform 
bacilli
1–10%
2 III >10 per cell >50% Cocci or chains of 
cocci
>10%
Score <3—no AV; score 3 to 4—light AV; score 5 to 6—moderate AV; score >6—severe AV. Lactobacillary grades: 
I—only numerous pleomorphic lactobacilli; IIa—dominance of lactobacilli, but other bacteria present; IIb—dominance 
of other bacteria, but still some lactobacilli present; III—lactobacilli absent or severely depressed and dominance of 
other bacteria. Use 400× magnification. HPF high power field. Adapted from Donders et al. [145]




Treatment of AV is not yet standardized and fur-
ther studies are needed in this specific field. The 
treatment is guided by the microscopy findings: It 
must be attempted to correct the atrophy (topical 
oestrogens), the inflammation (topical steroids) 
and the presence of bacteria (antiseptics, topical 
and antibiotic antiseptics). In one study, probiot-
ics have shown to increase the time to recurrence 
[136] (Table 24.10).
If antibiotics are chosen, preference should 
be given to topical formulations, to those active 
against Gram negative bacilli and Gram-positive 
cocci, and as innocuous as possible to  lactobacilli. 
The use of the antiseptic dequalinium chloride 
was less associated with Candida at the end of the 
treatment, when compared to antibiotics [118].
24.5  Cytolytic Vaginosis, 
Lactobacillosis 
and “Leptothrix”
The dominance of the vaginal milieu by lactoba-
cilli species and the consequent low pH is unique 
to the human species. Its main goal seems to be 
the protection against sexually transmitted infec-
tions (STIs) and, ultimately, the consequences of 
it in the offspring. In evolutionary terms, it may 
have happened as a consequence of the continu-
ous ovarian cycle (and, consequently, an increased 
risk of exposure to STIs, when compared to other 
species) or due to the high consumption of starch, 
which occurred after the agricultural revolution 
[80, 151]. Other authors have highlighted the 
need for a protective environment during delivery, 
as due to the disproportion between the head and 
the pelvis, the likelihood of vaginal wall lacera-
tions is higher than in other species. However, this 
unique situation can turn against the host [80].
Higher levels of oestrogens, as seen just before 
ovulation, are directly linked to the lactobacilli 
abundance, lower vaginal pH, thickening of the 
vaginal epithelium, and increased production of 
glycogen [80].
For still unknown reasons, sometimes the lac-
tobacilli can be a cause of cytolysis (cytolytic 
vaginosis [CV]), can be increased in number 
(lactobacillosis), or longer than normal (previ-
ously denominated “leptothrix”). These are con-
troversial entities, and it is still unknown whether 
or not they are part of the same spectrum. Some 
authors consider lactobacillosis and “leptothrix” 
as one single entity.
These are not infectious causes of “vaginitis”, 
but are important differential diagnosis of VVC, 
Cytolytic Vaginosis: Breaking the Myths
 – Lactobacilli are not always protective—
Increase in lactobacilli may cause cyto-
lytic vaginosis, a special form of 
sometimes symptomatic vaginal 
discharge
 – Cytolytic vaginosis symptoms closely 
mimic those of vulvovaginal candidiasis
Table 24.10 Treatment of Aerobic Vaginosis. Donders et al. [142]
Antiseptics Dequalinium chloride id for 6 days
Iodopovidone (Transient effect, low impact on 
lactobacilli, washing effect?)Chlorhexidine
Topical antibiotics Clindamycin cream 2% id for 2 weeks
Rifaximin 25–100 mg id for 6 days
Systemic antibiotics Moxifloxacin 400 mg id for 6 days (repeat if absence of 
microscopic cure)
Topical steroids Hydrocortisone cream 10% 3–5 times/week (vaginal) 




According to usual schemes
Probiotics L. acidophilus + estriol 30 μg id for 6–12 days
Other Nifuratel 500 mg id 10 days (topical or oral)
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which are commonly found in women with sus-
pected “resistant” or recurrent candidiasis.
24.5.1  Cytolytic Vaginosis
24.5.1.1  Aetiology
It has not been fully understood what leads to the 
overgrowth of lactobacilli in some women or why 
does it lead to the destruction of the intermediate 
cells of the vaginal epithelium. It is highly likely 
that hormones play a role in the development of 
CV, as it is more common—or more symptom-
atic, during the luteal phase, pregnancy or peri-
menopause [152].
The cytolysis may be the consequence of the 
very low pH, due to the increased degradation of 
glycogen by the large number of lactobacilli.
Lactobacilli, except for L. iners, produce 
both l- and d-lactic acid (L. iners produces only 
the l-isomer); vaginal cells produce only the l- 
isomer. An imbalance in the local ratio between 
the two isomers, in favour of the l-isomer, can be 
involved in the development of VC, by altering 
the expression of the extracellular matrix metal-
loproteinase inducer [153].
Most women with symptomatic CV were previ-
ously treated with repeated courses of antifungals, 
which lead some authors to try to establish an asso-
ciation. However, this association is more likely to 
be due to the fact that they were previously misdi-
agnosed as Candida and thus treated as so.
24.5.1.2  Prevalence 
and Epidemiology
The prevalence of CV in asymptomatic women 
ranges between 1 and 7%, peaking during the 
reproductive years [152]. Despite the now 
acknowledged racial differences in terms of 
vaginal microbiome composition, it is not known 
if it has any impact in the prevalence of CV.
24.5.1.3  Risk Factors 
and Associations
One study suggested that less sexually active 
women were more likely to have CV, but it can 
be biased, as the comparison group was with sex-
ual workers [154]. It has been suggested, also in 
one isolated study, that women with CV are less 
likely to have an abnormal Pap test, but we could 
not confirm it [155].
24.5.1.4  Signs and Symptoms
VC mimics the symptoms of VVC; almost all 
patients were previously treated with antifungals, 
either for a suspected diagnosis performed by a 
physician or by self-diagnosis.
The clinical history most of the times is 
enough to raise a high level of suspicion for CV.
The most striking symptom is burning, rather 
than pruritus. The typical discharge is white, 
sometimes lumpy and abundant (Fig.  24.16); 
some women will describe that it smells like 
vinegar. Dysuria and dyspareunia may also be 
among the list of symptoms. Symptoms tend be 
cyclic, aggravating in the luteal phase, peaking 
just before the menses. There is usually a great 
relief associated with menstruation or withdrawal 
bleeding. It is common that women report a tran-
sitory relief with the use of topical antifungals, 
but not oral formulations, probably due to a buff-
ering effect.
The vulvar exam may be unremarkable, or 
some degree of erythema and/or oedema can be 
present. Fissures are an uncommon feature.
24.5.1.5  Complications
The very few studies about CV usually did not 
address the issue of complications. In one single 
study, we found that CV is much more prevalent 
Fig. 24.16 Abundant, lumpy discharge in a woman with 
cytolytic vaginosis
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in women with localized provoked vulvodynia, 
when compared to healthy controls (16.5% vs. 
4.1%, p  =  0.000) [156]. However, women with 
vulvodynia tend to have less frequent intercourse 
and, as referred before, CV has been found to 
be more common in less sexually active women 
[154]. On the other side, there is a biological 
plausibility that the chronic exposure of the ves-
tibule to a very low pH, excessive amounts of 
H2O2, or the association to a specific lactobacil-
lus species can be involved in the development of 
some cases of vulvodynia. Ventolini et al. associ-
ated L. gasseri with vulvodynia, which can lead 
to the speculation that this can be a common link 
between the two entities [157].
24.5.1.6  Diagnosis
The diagnosis is made using the microscope 
(Table  24.12). It is characterized by the pres-
ence of an abundant number of lactobacilli, bare 
nuclei and cellular debris (in extreme cases, no 
intact cells are seen in the slide). Inflammation, 
clue cells, bacteria other than lactobacilli, and 
T. vaginalis are typically absent (Fig.  24.17). 
Although, per definition, the diagnosis implies 
the exclusion of the presence of Candida, given 
the typically low pH (<4.0–4.2) the coexistence 
of both is not rare.
Cultures for fungi can be used to exclude the 
presence of Candida.
24.5.1.7  Treatment
The treatment consists of increasing the pH of 
the vagina (buffer effect), which will diminish the 
load of lactobacilli in the vagina and ameliorate 
the symptoms.
Vaginal irrigations with sodium bicarbonate 
are highly effective in controlling the symp-
toms. While some authors recommend sitz 
baths, in our experience irrigations are much 
more effective (Table 24.11). In recurrent cases, 
if a pattern is identified, treatment should be 
started 24–48 h prior to the anticipated moment 
of onset [159].
24.5.2  Lactobacillosis
This entity is characterized by the overgrowth of 
lactobacilli, without cellular lysis (Fig.  24.18). 
When symptomatic, it is very similar to CV. There 
is no epidemiological data in the literature con-
cerning lactobacillosis.
The diagnosis is established by a normal or 
reduced pH, cultures negative for Candida, and, 
most important, by an increased number of lac-
tobacilli in microscopy, without other types of 
Fig. 24.17 Cytolytic vaginosis. Bare nuclei (white 
arrows), cellular debris (white arrows) and abundant 
lactobacilli Fig. 24.18 Lactobacillosis (phase contrast 400×)
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bacteria, cytolysis, inflammation, clue cells, or 
T. vaginalis (Table 24.12).
It is believed that it is self-limited, thus expect-
ant management is an option. In cases in which 
treatment is needed, it is similar to that of CV 
(Table 24.11).
24.5.3  “Leptothrix”
Leptothrix is a controversial entity; even those who 
acknowledge its existence do not agree in how it 
should be designated (alternative names include 
“fusiform lactobacilli”) [160]. It is characterized 
Table 24.12 Wet mount characterization and differential diagnosis of vulvovaginitis
Presence of 
parabasal/
basal cells Lactobacilli Inflammation Other Notes
Candidiasis or 
candidosis
− Normal Can be present Hyphae, 
pseudohyphae, 
spores
Inflammation, if present, 
usually without toxic 
leucocytes
C. glabrata presents only as 
blastospores
Presence of pseudohyphae is 
highly suggestive of infection 
rather than colonization
Blastospores of C. 
parapsilosis and S. cerevisiae 
are larger than those of C. 
glabrata












Frequently associated with 
BV. If slide kept warm and 
microscopy performed 
immediately after collection, 
the likelihood of seeing 





− Clue cells If inflammation is present, 










− Increased − Bare nuclei and 
cellular debris
−
Lactobacillosis − Increased 
and long
− − −
Leptothrix − Long − − Lactobacilli longer than in 
lactobacillosis
Can coexist with normal 
lactobacilli, BV, or even TV
Table 24.11 Treatment of CV, lactobacillosis and leptothrix
Cytolytic vaginosis Sodium bicarbonate 30–40 mg should be diluted in 1 L of warm water and 
vaginal irrigations performed daily for 2 weeks
Maintenance, if needed, should be kept as the 
minimum required to control the symptoms
Lactobacillosis
Leptothrix Amoxicillin + clavulanate 500/125 First choice
3 id for 7 days
Doxycycline 100 mg [158] If allergic to penicillin
2 id for 10 days
Nifuratel 200 mg Alternative needing further tests
3 id for 7 days
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by the presence of long, filamentous lactobacilli, 
sometimes with segmentation and/or sporulation 
(Fig. 24.19). Its size can be 8–15 times that of a 
normal lactobacillus [161]. It can totally dominate 
the flora or be associated with normal lactobacilli, 
lactobacillosis [158], or even BV type flora and 
T. vaginalis. In a Swedish study, its prevalence in 
a cohort of women without BV was 8%. These 
authors identified these bacteria as L. gasseri [160].
There is some speculation that these lactoba-
cilli may be the consequence of the previous use 
of antibiotics or antifungals.
Horowitz et al. described women with cycli-
cal symptoms of vulvar discomfort and vaginal 
discharge during the luteal phase, associated 
with the presence of long and serpiginous 
lactobacilli.
The diagnosis is easily made by microscopy, 
by the presence of the typical long bacteria, 
that should not be confused with Candida or 
Actinomyces (Table 24.12).
Treatment with oral antibiotics has proven to be 
highly effective, both in the control and symptoms 
and in the elimination of the bacteria [158]. The 
first choice is amoxicillin + clavulanate; in women 
allergic to penicillin, doxycycline is an alterna-
tive [158]. Nifuratel has also been tested, but with 
much higher rates of relapse [162] (Table 24.11).
In contrast to other authors’ experience, we have 
seen recurrences, even after successful treatment.
24.6  Other Conditions to Consider 
in the Differential Diagnosis 
of Vaginal Discharge
Several other conditions can present in similar 
ways to vulvovaginitis and must be considered in 
the differential diagnosis.
Postmenopausal vaginal atrophy can pres-
ent in two ways: (1) without discharge (on 
microscopy there is paucity of epithelial cells 
and no inflammation) and (2) with purulent 
discharge (abundance of deep layer cells and 
inflammation—“atrophic vaginitis”). In 2014, 
the North American Menopause Society and the 
International Society for the Study of Women’s 
Sexual Health proposed that “vaginal atrophy” 
and “atrophic vaginitis” should be replaced 
by “genitourinary syndrome of menopause”. 
However, we disagree with this concept, as it 
cannot be considered a syndrome (which, by def-
inition, is a particular abnormality or condition), 
no minimum number of criteria was defined, the 
list of signs and symptoms is not specific, and 
some of the mainstays for its creation are highly 
debatable (like “atrophy” having a negative con-
notation or “vagina” not being a well accepted 
term) [163].
Vaginal involvement of erosive lichen planus 
can manifest itself also with by a purulent dis-
charge, sometimes with more or less extensive 
formation of synechia.
Other causes to be considered include allergic 
and contact vaginitis, as well as cervical ectopy 
[53] (Table 24.13).
Fig. 24.19 Leptothrix (phase contrast 400×)
Vaginal Atrophy: Breaking the Myth
“Vaginal atrophy” and “atrophic vaginitis” 
may be associated with vaginal discharge. 
These terms have recently been renamed: 
“genitourinary syndrome of menopause”. 
However, no minimum number of criteria 
was defined, the list of signs and symptoms 
is not specific, and some of the mainstays 
for its creation are highly debatable.
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Table 24.13 Clinical characteristics and potential risks of different causes of vulvovaginitis
pH Whiff test
Variation of symptoms 
during ovarian cycle Symptoms Signs Risks
Candidiasis Normal
(but can occur at any 
pH; most likely to 
be symptomatic at 
low pH)
− Worsening during 






If burning is the main 





oedema, white, curdy 
discharge, without 
foul smell
  •  Limited data relating it 
to bad obstetrical 
outcomes
  • Increased risk of HIV














can have a rotten 
smell
  •  Adverse obstetrical 
outcomes
  • STIs (HIV)
Bacterial vaginosis Increased (>4.5) + Worsening of 
symptoms during 
menses
Fishy smell, mild 
burning
Grey or yellow, thin, 
adherent discharge
  •  Adverse obstetrical and 
neonatal outcomes
  • STIs
  • Cervical dysplasia/
cancer
Aerobic vaginitis Increased (usually 
more than in BV: 
>5)
− Worsening of 
symptoms during 
menses?
Rotten wood smell 
discharge; burning, 
stinging, dyspareunia
Yellow or green 
purulent discharge; 
erosions, enantema
  •  Adverse obstetrical and 
neonatal outcomes
  • STIs
  • Abnormal pap tests
Cytolytic vaginosis Lower than normal − Worsening during 







  • Vulvodynia (?)
Lactobacillosis Lower than normal − Worsening during 





  • Not reported
Leptothrix Normal/low (?) − ? Asymptomatic most of 
time times
Burning
Normal   • Not reported
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